Product Description: Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.
Applications: COVID-19-anti-virus
Formula: C23H24N4O6
References: [1]Jain J, et al. VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37./[2]Markland W, et al. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000 Apr;44(4):859-66./[3]Decker CJ, et al. The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice. Drugs Exp Clin Res. 2001;27(3):89-95.
CAS Number: 198821-22-6
Molecular Weight: 452.46
Compound Purity: 99.64
Research Area: Infection; Cancer
Solubility: DMSO : ≥ 31 mg/mL
Target: Dengue virus;Flavivirus;HBV;HCV